Cargando…

Real-World Patterns of Utilization and Costs Associated with Second-Generation Oral Antipsychotic Medication for the Treatment of Bipolar Disorder: A Literature Review

OBJECTIVE: Treatment with second-generation antipsychotics (SGAs) for bipolar disorder, including bipolar I disorder (BD-I), is common. This review evaluated real-world utilization patterns with oral SGAs in the United States (US) for bipolar disorder (and BD-I specifically when reported) and econom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doane, Michael J, Ogden, Kristine, Bessonova, Leona, O’Sullivan, Amy K, Tohen, Mauricio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896797/ https://www.ncbi.nlm.nih.gov/pubmed/33623386 http://dx.doi.org/10.2147/NDT.S280051

Ejemplares similares

The Economic Burden of Bipolar Disorder in the United States: A Systematic Literature Review
por: Bessonova, Leona, et al.
Publicado: (2020)

Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder
por: Doane, Michael J., et al.
Publicado: (2022)

Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States
por: Martin, Amber, et al.
Publicado: (2022)

Antipsychotic treatment experiences of people with bipolar I disorder: patient perspectives from an online survey
por: Bessonova, Leona, et al.
Publicado: (2020)

Unmet needs with antipsychotic treatment in schizophrenia and bipolar I disorder: patient perspectives from qualitative focus groups
por: Doane, Michael J., et al.
Publicado: (2023)

Antipsychotic Treatment Experiences of People with Schizophrenia: Patient Perspectives from an Online Survey
por: Doane, Michael J, et al.
Publicado: (2020)

Controversies in bipolar disorder; role of second-generation antipsychotic for maintenance therapy
por: Jauhar, Sameer, et al.
Publicado: (2019)

Association of Lithium and Second-Generation Antipsychotics with Neurocognition in Youth with Bipolar Disorder
por: Jiang, Xinyue, et al.
Publicado: (2022)

Treatment Guidelines in Bipolar Disorders and the Importance of Proper Clinical Trial Design
por: Tohen, Mauricio
Publicado: (2017)

Real‐world effectiveness of antipsychotics
por: Tiihonen, J.
Publicado: (2016)

Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data
por: Tohen, Mauricio
Publicado: (2021)

Second-Generation Antipsychotics’ Effectiveness and Tolerability: A Review of Real-World Studies in Patients with Schizophrenia and Related Disorders
por: Fabrazzo, Michele, et al.
Publicado: (2022)

Second‐generation antipsychotic long‐acting injections in bipolar disorder: Systematic review and meta‐analysis
por: Prajapati, Asta R., et al.
Publicado: (2018)

S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
por: Greene, Mallik, et al.
Publicado: (2018)

Patterns of initiation of second generation antipsychotics for bipolar disorder: a month-by-month analysis of provider behavior
por: Miller, Christopher J, et al.
Publicado: (2014)

Changes in Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics (LAIs), Including Telepsychiatry Use, During the COVID-19 Pandemic
por: Haider, Batool, et al.
Publicado: (2023)

Electroconvulsive therapy electrode placement for bipolar state-related targeted engagement
por: Abbott, Christopher C., et al.
Publicado: (2019)

Functional outcome assessment in bipolar disorder: A systematic literature review
por: Chen, Maxine, et al.
Publicado: (2019)

Real World Haskell
por: O'Sullivan, Bryan, et al.
Publicado: (2008)

Cardiometabolic comorbidities, readmission, and costs in schizophrenia and bipolar disorder: a real-world analysis
por: Correll, Christoph U., et al.
Publicado: (2017)

The Use of Second-Generation Antipsychotics in Patients with Severe Schizophrenia in the Real World: The Role of the Route of Administration and Dosage—A 5-Year Follow-Up
por: Fernández-Miranda, Juan J., et al.
Publicado: (2022)

Updating the Comparative Evidence on Second‐Generation Antipsychotic Use With Schizophrenia
por: McDonagh, Marian S., et al.
Publicado: (2020)

Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
por: Divac, Nevena, et al.
Publicado: (2014)

Persistence of Antipsychotic Use After Clozapine Discontinuation: A Real‐World Study Across Antipsychotics
por: Stam, Noraly, et al.
Publicado: (2020)

Aggression among 216 patients with a first-psychotic episode of bipolar I disorder
por: Khalsa, Hari-Mandir K., et al.
Publicado: (2018)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder
por: Flowers, Stephanie A., et al.
Publicado: (2016)

Effects of Lithium Combined with Second-Generation Antipsychotics for the Treatment of Manic Episodes in Patients with Bipolar Disorder: A Naturalistic Study in China
por: Liu, Yang, et al.
Publicado: (2020)

Cost‐effectiveness of second‐line ipilimumab for metastatic melanoma: A real‐world population‐based cohort study of resource utilization
por: Lu, Brandon, et al.
Publicado: (2023)

Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
por: Bernardo, Miquel, et al.
Publicado: (2021)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2022)

Long-acting new generation antipsychotics in the maintenance treatment of bipolar disorders
por: Yavuz, E., et al.
Publicado: (2023)

Arterial Stiffness in Patients Taking Second-generation Antipsychotics
por: Fındıklı, Ebru, et al.
Publicado: (2016)

Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia
por: Caruso, Giuseppe, et al.
Publicado: (2020)

The use of atypical antipsychotics in Bipolar Spectrum disorders
por: Grünze, H., et al.
Publicado: (2003)

Second-Generation Insulin Analogues – a Review of Recent Real-World Data and Forthcoming Head-to-Head Comparisons
por: Mauricio, Didac, et al.
Publicado: (2018)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

First-generation vs second-generation antipsychotic drugs: The ongoing saga
por: Gupta, Sumeet
Publicado: (2010)

Health resource utilization, costs, and community treatment order status before and after the initiation of second-generation long acting-injectable antipsychotics in patients with schizophrenia in Alberta, Canada
por: Chue, P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_erafclv3jhadl52n4i8lppdbnr